KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Interest & Investment Income (2019 - 2026)

GoodRx Holdings' Interest & Investment Income history spans 7 years, with the latest figure at $1.9 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 58.82% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.9 million, a 53.02% decrease, with the full-year FY2025 number at $10.9 million, down 53.02% from a year prior.
  • Interest & Investment Income hit $1.9 million in Q4 2025 for GoodRx Holdings, down from $2.3 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for GDRX hit a ceiling of $8.6 million in Q3 2023 and a floor of $13000.0 in Q2 2021.
  • Historically, Interest & Investment Income has averaged $3.8 million across 5 years, with a median of $3.4 million in 2022.
  • Biggest five-year swings in Interest & Investment Income: plummeted 78.67% in 2021 and later soared 31929.41% in 2022.
  • Tracing GDRX's Interest & Investment Income over 5 years: stood at $17000.0 in 2021, then soared by 31929.41% to $5.4 million in 2022, then soared by 55.63% to $8.5 million in 2023, then tumbled by 45.87% to $4.6 million in 2024, then crashed by 58.82% to $1.9 million in 2025.
  • Business Quant data shows Interest & Investment Income for GDRX at $1.9 million in Q4 2025, $2.3 million in Q3 2025, and $2.8 million in Q2 2025.